Reinfection With SARS-CoV-2: Implications for Vaccines

Area of Science:

• Virology
• Immunology
• Epidemiology

Background:

• The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises questions about the duration of protective immunity.
• Increasing reports of SARS-CoV-2 reinfection highlight the uncertainty surrounding long-term immunity.
• Understanding the persistence of antibodies and T cells post-infection is crucial.

Purpose of the Study:

• To review current knowledge on the duration of immunity and reinfection rates for coronaviruses, including SARS-CoV-2.
• To compare SARS-CoV-2 immunity with that of other respiratory viruses like influenza and seasonal coronaviruses.
• To discuss the implications for public health strategies, including protective measures and vaccine development for previously infected individuals.

Main Methods:

• Literature review of studies on coronavirus immunity and reinfection.
• Analysis of data on antibody and T cell persistence after SARS-CoV-2 infection.
• Comparative analysis with immunity data from other viral infections and vaccines.

Main Results:

• The duration of protective immunity to SARS-CoV-2 remains largely unknown.
• Reinfection with SARS-CoV-2 is occurring with increasing frequency.
• Antibody persistence for other respiratory viruses like influenza and seasonal coronaviruses is often limited to months or a few years, with common reinfections.

Conclusions:

• The limited duration of immunity observed for other respiratory viruses suggests potential for waning immunity and reinfection with SARS-CoV-2.
• Findings have significant implications for the necessity of ongoing protective measures.
• The duration of immunity influences strategies for developing and deploying vaccines for individuals previously infected with SARS-CoV-2.